Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.0K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.0K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving Prognostication for Cutaneous Squamous Cell Carcinoma.

The British journal of dermatology·2026
Same author

Mohs micrographic surgery versus wide local excision for recurrent cutaneous squamous cell carcinoma.

JAAD international·2026
Same author

Response to Wang et al., "Time as a Substantial Confounder in Evaluating Integrated Multidisciplinary Care for Advanced Cutaneous Squamous Cell Carcinoma".

Journal of the American Academy of Dermatology·2026
Same author

Prognostic determinants of early and late relapse in cutaneous squamous cell carcinoma: A multicenter retrospective cohort study.

Journal of the American Academy of Dermatology·2026
Same author

Mohs surgery reduces recurrence for dermatofibrosarcoma protuberans: A multicentre cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

International Variability in Cutaneous Squamous Cell Carcinoma Management and Outcomes: An Exploratory Analysis From the United States, Spain, and Brazil.

International journal of dermatology·2026
Same journal

A Pilot Study on Disposal Practices and Environmental Awareness of Insulin-Related Devices Among People With Diabetes.

Journal of diabetes science and technology·2026
Same journal

Quality of In-Use Insulin Under Real-World Storage Conditions in Mwanza, Tanzania.

Journal of diabetes science and technology·2026
Same journal

Continuous Glucose Monitoring Metrics for Predicting Adverse Neonatal Outcomes in Individuals Undergoing Gestational Diabetes Screening.

Journal of diabetes science and technology·2026
Same journal

Diabetes Technologist: Optimal Use of Technology in Everyday Practice.

Journal of diabetes science and technology·2026
Same journal

AI-Driven Diabetes Care and Its Relevance in the Philippine Context: Opportunities and Persistent Digital Barriers.

Journal of diabetes science and technology·2026
Same journal

Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.

Journal of diabetes science and technology·2026
See all related articles

Related Experiment Video

Updated: Apr 28, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K

Patient Perspectives on Biosimilar Insulin.

Alasdair R Wilkins1, Manu V Venkat1, Adam S Brown1

  • 1Close Concerns, San Francisco, CA, USA.

Journal of Diabetes Science and Technology
|May 31, 2014
PubMed
Summary
This summary is machine-generated.

Most patients with diabetes are open to using less expensive biosimilar insulins. However, addressing concerns about efficacy and safety is crucial for widespread adoption.

Keywords:
biosimilar insulincostsdiabetesinsulin formulationsinsulin therapy

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.7K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11.5K
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.0K

Area of Science:

  • Endocrinology
  • Pharmacoeconomics
  • Patient-Reported Outcomes

Background:

  • The upcoming market entry of numerous biosimilar insulins necessitates understanding patient acceptance.
  • Patient perspectives are vital for the successful integration of biosimilar insulins into diabetes management.
  • Previous research has not fully captured patient attitudes towards biosimilar insulin adoption.

Purpose of the Study:

  • To investigate patient perspectives on the potential use of biosimilar insulins.
  • To identify key patient concerns regarding biosimilar insulin efficacy, safety, and administration.
  • To gauge patient willingness to switch to less expensive biosimilar insulin options.

Main Methods:

  • A large-scale survey (N = 3214) was administered to patients with type 1 or type 2 diabetes.
  • The survey assessed patient likelihood of switching to a hypothetical, provider-approved, less expensive biosimilar insulin.
  • Data were collected on patient concerns, including efficacy, side effects, and device design.

Main Results:

  • Approximately 66% of surveyed patients indicated they would "definitely" or "likely" use a biosimilar insulin.
  • 17% of respondents expressed they were "unlikely" or would "definitely not use" biosimilar insulins.
  • Type 2 diabetes patients showed a slightly higher propensity to consider biosimilar insulins compared to type 1 patients.

Conclusions:

  • The majority of patients are receptive to considering biosimilar insulins, driven partly by potential cost savings.
  • Patient concerns regarding efficacy, safety, and drug delivery must be proactively addressed by manufacturers.
  • Successful uptake of biosimilar insulins will depend on building patient trust and ensuring perceived quality equivalence.